Pharmacotherapy for nontuberculous mycobacterial pulmonary disease

Manasa Velagapudi, Michael J. Sanley, Sumaya Ased, Chris Destache, Mark A. Malesker

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose: To provide an updated review of the diagnosis and pharmacotherapy of nontuberculous mycobacteria pulmonary disease (NTM-PD) and summarize guideline recommendations for an interdisciplinary treatment approach. Summary: A systemic approach was taken in which all articles in English in MEDLINE and PubMed were reviewed. The US National Library of Medicine's DailyMed database was used to assess drug package inserts. Analysis of NTM treatment guidelines is summarized in the article with a focus on medications, dosing, interactions, and medication monitoring. Conclusion: It is critical to manage patients with NTM with a multidisciplinary team approach. Treatment is prolonged and expensive, and the potential for drug toxicity, adverse effects, and drug interactions requires monitoring. Clinical pharmacists play a role in the management of NTM.

Original languageEnglish (US)
Pages (from-to)437-445
Number of pages9
JournalAmerican Journal of Health-System Pharmacy
Volume79
Issue number6
DOIs
StatePublished - Mar 15 2022
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Health Policy

Fingerprint

Dive into the research topics of 'Pharmacotherapy for nontuberculous mycobacterial pulmonary disease'. Together they form a unique fingerprint.

Cite this